Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer

Author(s): Bradley J. Stish, MD¹; Gina L. Mazza, PhD²; Jones T. Nauseef, MD, PhD³; Michael Sandon Humeniuk, MD⁴; Thomas J. Smith, MD⁵; Cindy Tofthagen, PhD, RN⁶; Dayssy Alexandra Diaz Pardo, MD⁷; Christopher Chay, MD⁸; Andrew J. Huang, MD⁹; Kushal Naha, MD¹⁰; Scott T. Tagawa, MD³; Selina Chow, MD¹¹; Kathryn J. Ruddy, MD¹²; Maryam B. Lustberg, MD, MPH¹³; Lucile L. Adams-Campbell, PhD¹⁴; Paul J. Novotny, MS¹⁵; Charles L. Loprinzi, MD¹²;

Source: DOI: 10.1200/JCO-25-01486

Dr. Anjan Patel's Thoughts

Solid pragmatic phase II showing oxybutynin 2.5mg and 5mg BID (twice a day) both beat placebo for hot flash reduction in men on androgen-deprivation therapy (ADT), with no serious toxicities beyond expected dry mouth. Given that venlafaxine failed in this population and megestrol/medroxyprogesterone carry real concerns, this gives us an evidence-based option we can feel good about reaching for, especially in patients who also have urinary symptoms. Neurokinin B (NKB) antagonists are coming but not yet studied here, so oxybutynin fills a real gap now.

PURPOSE

Hot flashes are a common side effect reported by men receiving androgen-deprivation therapy (ADT) for the treatment of prostate cancer. We sought to determine whether oxybutynin could improve hot flash symptoms in men with prostate cancer.

PATIENTS AND METHODS

Patients with prostate cancer receiving a stable regimen of ADT with least 28 hot flashes per week were randomly assigned to receive either oxybutynin 2.5 mg twice daily, oxybutynin 5 mg twice daily, or matching placebo for 6 weeks. The primary end point was the change in patient-reported hot flash scores since baseline 6 weeks. Additional outcomes included incidence of adverse events (AEs), changes since baseline in Hot Flash–Related Daily Interference Scale (HFRDIS) scores, and patient-reported symptoms.

RESULTS

Eighty-eight patients were enrolled, with the 81 participants eligible for final analysis reporting an average of 10.1 (standard deviation [SD], 5.55) hot flashes per day and an average daily hot flash score of 18.2 (SD, 13.5) included in final analysis. On average, patients on the placebo arm, 2.5 mg oxybutynin arm, and 5 mg oxybutynin arm had reductions in hot flashes/day of 2.15, 4.77 (P = .02), and 6.89 (P < .001), respectively. Daily hot flash scores for placebo, 2.5 mg oxybutynin, and 5 mg oxybutynin reduced by an average of 4.85, 9.94 (P = .07), and 13.95 (P = .002) points, respectively. No treatment-related grade 3+ AEs occurred. HFRDIS total scores improved by 14.2 and 20.7 points in the 2.5 mg (P = .042) and 5 mg (P < .01) oxybutynin arms, respectively, compared with a 3.1-point improvement with placebo.

CONCLUSION

Oxybutynin is superior to a placebo for the management of ADT-associated hot flashes in men with prostate cancer.

Author Affiliations

¹Mayo Clinic Department of Radiation Oncology, Rochester, MN; ²Alliance Statistics and Data Management Center, Mayo Clinic, Scottsdale, AZ; ³Division of Hematology & Medical Oncology, Weill Cornell Medicine; Sandra and Edward Meyer Cancer Center, New York, NY; ⁴Gibbs Cancer Center, Spartanburg Regional Healthcare System, Spartanburg, SC; ⁵Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; ⁶Mayo Clinic Division of Nursing Research, Jacksonville, FL; ⁷The Ohio State University Comprehensive Cancer Center, Columbus, OH; ⁸SCOR—Messino Cancer Centers, Ashville, NC; ⁹Aspirus Regional Cancer Center, Wausau, WI; ¹⁰MU Health—University Hospital/Ellis Fischel Cancer Center, Columbia, MO; ¹¹Alliance Protocol Operations Office, University of Chicago, Chicago, IL; ¹²Division of Medical Oncology, Mayo Clinic, Rochester, MN; ¹³Department of Medicine, School of Medicine, Yale University, New Haven, CT; ¹⁴Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; ¹⁵Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide

An important post-hoc analysis from ARCHES and PROSPER that quantifies something we've suspected clinically, roughly 1 in 4 enzalutamide-treated patients who progress radiographically have no prostate-specific antigen (PSA) rise, and the majority won't meet PCWG2/3 PSA progression criteria. Liver metastases were 5-fold more common at radiographic progression on enzalutamide versus control, suggesting lineage plasticity and AR-independent clones are the culprit. Bottom line for practice: don't wait for PSA to rise before imaging your metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC) patients on ARPIs, periodic cross-sectional imaging, especially in the first two years, is warranted regardless of PSA trend.

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

Overall survival was 78.9% in the combination group compared with 69.5% in the leuprolide-alone group (HR 0.60). Enzalutamide monotherapy resulted in an overall survival of 73.1%, which was not statistically significant. We were already aware of the progression-free survival benefit; now we have overall survival data. This case was also presented in the MOC questions, where the correct answer was to add enzalutamide for a patient with a rising PSA on an LHRH agonist without imaging evidence of disease.

Metformin Active Surveillance Trial in Low-Risk Prostate Cancer

Metformin did not significantly reduce the risk of disease progression compared with active surveillance in patients with low-risk prostate cancer.

177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

For our radiation oncology colleagues, the addition of PSMA-directed therapy prior to stereotactic body radiation therapy (SBRT) improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. Two cycles of PSMA-directed therapy were administered before SBRT.

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

A new MMAI-derived digital pathology biomarker was trained and prospectively validated across multiple NRG/RTOG phase III trials, including RTOG 9202 (N=1,192), to predict which high-risk/locally advanced PCa patients benefit from LT-ADT vs ST-ADT with RT. In the overall cohort, LT-ADT reduced DM (17% vs 26% at 15 years) and DDM (15% vs 23% at 15 years), but this benefit was limited to biomarker-positive patients (DM: 19% vs 33%; DDM: 19% vs 30%), with no advantage seen in biomarker-negative patients (DM: 11% vs 11%; DDM: 9% vs 10%). This tool could allow about a third of our "high-risk" patients to avoid two extra years of ADT without compromising metastasis outcomes, while ensuring we intensify for those most likely to benefit. In short, this is a practical step toward personalizing ADT duration and sparing toxicity for a significant subset of our patients.